** JonesTrading starts coverage on drug developer Sagimet Biosciences SGMT.O with "buy" rating, sets PT at $42
** PT represents 900% upside to stock's last close
** Brokerage says co's experimental drug, denifanstat, is "overlooked potential" in treating metabolic dysfunction-associated steatohepatitis (MASH)
** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage
** JonesTrading notes denifanstat has " best-in-disease potential for fibrosis improvement as GLP-1 combo" with "well-derisked lead asset" in expanding market
** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034
** SGMT fell 15.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.